Abstract
Pharmacogenomics, the science of individualizing drug therapy based on the
genetic makeup of individual patients, offers an unusual opportunity for
future market growth. Applying pharmacogenomics would allow doctors to treat
specific segments of the population based on their particular responses to a
drug. The knowledge of the likely effectiveness of a drug in a patient makes
the drug more reliable, and fewer drugs would have to be taken off the market
due to adverse reactions in some, but not all, of the patients to whom they
were administered. Additionally, reducing the occurrence of adverse effects to
a drug effectually reduces the cost of patient care overall. This TriMark
Publications study examines the market for diagnostic tests based on this
science and the clinical measurement methods, the reagents and supplies being
utilized in clinical medicine and the pharmaceutical industry. This report
presents an overview of the latest information regarding emerging new products
and industry trends and will not only quantify, but also, qualify the
pharmacogenomic market segments as an area of research, product development
and investment opportunity. Forecasts of the pharmacogenomic market and an
analysis of products in the worldwide diagnostics market will provide a basis
for understanding the significance of past developments and the immense
possibilities of the future.
| 
View Cart
